Pfizer, Novartis say meningitis vaccine scope too narrow
A U.S. Centers for Disease Control and Prevention (CDC) advisory committee on Thursday recommended meningitis B vaccines for people at high risk aged 10 to 25, a population that Pfizer Inc and Novartis criticized as too narrow. Pfizer’s Trumenba, like Novartis’ new vaccine Bexsero, recently won U.S. marketing approval to treat the “B” strain of the deadly bacterium in that age group.